Episode 83
Biotech Hangout
00:00
Recent Licensing Deal: Vertex and Editas
This chapter discusses the recent licensing deal between Vertex and Editas for their CRISPR-Cas9 technology, putting an end to the ongoing patent fight between various CRISPR companies. It highlights the implications of this deal for Editas and emphasizes the importance of non-dilutive capital for their development. The speakers express their skepticism towards the significance of patent headlines, stating that similar situations often end up being less impactful than initially anticipated.
Transcript
Play full episode
